Paper Details

  1. Home
  2. Paper Details

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.

Author: BahcallMagda, ChopadePratik R, DholakiaKshiti H, GokhalePrafulla C, GuoJiannan, GuoSujuan, HongFangxin, JännePasi A, KimNam Doo, KirschmeierPaul T, KuangYanan, KöhlerJens, LauChristie J, PaweletzCloud P, SimTaebo, TausLuke J, WangStephen, WeiZihan

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

MET-targeted therapies are effective for treating <i>MET</i>-amplified and <i>MET</i> exon 14 deletion mutant lung cancers. However, resistance to these therapies is a major concern. This study found that combining type I and type II MET tyrosine kinase inhibitors (TKIs) effectively prevented the emergence of drug-resistant clones in vitro and in vivo. These findings suggest that combination therapy may be a valuable approach to overcoming drug resistance in MET-driven lung cancers.
Paper Details　
Original Abstract of the Article :
MET-targeted therapies are clinically effective in <i>MET</i>-amplified and <i>MET</i> exon 14 deletion mutant (<i>MET</i>ex14) non-small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/34789563

データ提供：米国国立医学図書館（NLM）

MET-Targeted Therapies: A New Frontier in Cancer Treatment

MET-targeted therapies are showing promise in treating certain types of cancer, but drug resistance remains a challenge. This study investigates the potential of combining type I and type II MET tyrosine kinase inhibitors (TKIs) to overcome resistance. It's like finding a new way to navigate a labyrinthine desert—seeking to overcome obstacles and find a path to success.

Combination Therapy: A New Strategy for Combating Resistance

The researchers found that combining capmatinib (type I TKI) and merestinib (type II TKI) resulted in no resistant clones in vitro. This is like using a combination of tools to navigate a difficult terrain—achieving greater success with a combined approach. The findings suggest that this combination therapy could be a valuable strategy for preventing drug resistance in MET-driven cancers.

The Promise of a Synergistic Approach

This research highlights the potential of combining different types of TKIs to combat drug resistance in cancer treatment. It's like discovering a new oasis in the desert—offering a potential solution to a difficult problem. This study underscores the importance of exploring innovative approaches to cancer therapy, seeking to improve patient outcomes and bring hope to those facing this challenge.

Dr. Camel's Conclusion

This study suggests that combining type I and type II MET TKIs could be a promising strategy for overcoming drug resistance in MET-driven cancers. It's a reminder that the fight against cancer often requires innovative approaches and a willingness to explore new frontiers. As researchers, we must continue to seek out new and effective strategies to combat this disease, bringing hope and a promise of a brighter future for patients.

Date :
  1. Date Completed 2022-03-29
  2. Date Revised 2022-08-02
Further Info :

Pubmed ID

34789563

DOI: Digital Object Identifier

NIHMS1757573

Related Literature

Article Analysis
・Effects of capmatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.